

## Oncology Today with Dr Neil Love: Non-Small Cell Lung Cancer with KRAS Mutations

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Approximately what proportion of KRAS mutations in non-small cell lung cancer (NSCLC) are KRAS G12C point mutations?
  - a. Less than 1%
  - b. 9%
  - c. 19%
  - d. 39%
2. What was the overall response rate in the CodeBreaK 100 study evaluating sotorasib for patients with previously treated locally advanced or metastatic NSCLC with a KRAS G12C mutation?
  - a. 10.7%
  - b. 20.7%
  - c. 40.7%
  - d. 60.7%
3. Which dose and schedule of adagrasib was evaluated for patients with previously treated NSCLC harboring a KRAS G12C mutation in the KRYSTAL-1 study?
  - a. 400 mg once daily
  - b. 400 mg twice daily
  - c. 600 mg once daily
  - d. 600 mg twice daily
4. What was the most common any-grade treatment-related adverse event observed with sotorasib in patients with previously treated NSCLC with a KRAS G12C mutation in the CodeBreaK 100 study?
  - a. Decreased appetite
  - b. Diarrhea
  - c. Fatigue
  - d. Thrombocytopenia
5. In the KRYSTAL-1 study evaluating adagrasib for patients with previously treated NSCLC with a KRAS G12C mutation, what proportion of patients received a dose reduction due to treatment-related adverse events?
  - a. 12%
  - b. 32%
  - c. 52%
  - d. More than 70%